细胞穿透肽介导的治疗药物眼内递药。
Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides.
机构信息
Department of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL 60612, USA.
Department of Ophthalmology and Visual Sciences, University of Illinois College of Medicine, Chicago, IL 60612, USA.
出版信息
Cells. 2023 Apr 1;12(7):1071. doi: 10.3390/cells12071071.
Cell-penetrating peptides (CPPs) are short peptides with the ability to translocate through the cell membrane to facilitate their cellular uptake. CPPs can be used as drug-delivery systems for molecules that are difficult to uptake. Ocular drug delivery is challenging due to the structural and physiological complexity of the eye. CPPs may be tailored to overcome this challenge, facilitating cellular uptake and delivery to the targeted area. Retinal diseases occur at the posterior pole of the eye; thus, intravitreal injections are needed to deliver drugs at an effective concentration in situ. However, frequent injections have risks of causing vision-threatening complications. Recent investigations have focused on developing long-acting drugs and drug delivery systems to reduce the frequency of injections. In fact, conjugation with CPP could deliver FDA-approved drugs to the back of the eye, as seen by topical application in animal models. This review summarizes recent advances in CPPs, protein/peptide-based drugs for eye diseases, and the use of CPPs for drug delivery based on systematic searches in PubMed and clinical trials. We highlight targeted therapies and explore the potential of CPPs and peptide-based drugs for eye diseases.
细胞穿透肽(CPPs)是具有穿过细胞膜能力的短肽,可促进其细胞摄取。CPP 可作为难以摄取的分子的药物传递系统。由于眼睛的结构和生理复杂性,眼部药物输送具有挑战性。CPP 可以定制以克服这一挑战,促进细胞摄取并将药物递送到靶向区域。视网膜疾病发生在眼睛的后极;因此,需要玻璃体内注射以在原位达到有效浓度的药物。然而,频繁注射有引起威胁视力的并发症的风险。最近的研究集中在开发长效药物和药物传递系统,以减少注射的频率。事实上,通过在动物模型中进行局部应用,与 CPP 的缀合可以将 FDA 批准的药物递送到眼睛的后部。本文综述了 CPPs、用于眼部疾病的蛋白质/肽类药物以及基于 CPP 的药物传递在 PubMed 和临床试验中的最新进展。我们重点介绍了靶向治疗,并探讨了 CPP 和基于肽的药物治疗眼部疾病的潜力。